Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children
|ClinicalTrials.gov Identifier: NCT00691288|
Recruitment Status : Terminated (Unable to enroll sufficient patients)
First Posted : June 5, 2008
Last Update Posted : June 12, 2014
|Condition or disease||Intervention/treatment||Phase|
|Hypertriglyceridemia||Drug: Omega Pure followed by placebo Drug: Placebo followed by Omega Pure||Phase 2|
There are no guidelines as to the clinical threshold at which treatment for hypertriglyceridemia is necessary in pediatric populations, and extreme hypertriglyceridemia is relatively infrequent in HIV-infected children. Adult studies have suggested that there is a proportionate reduction in triglycerides of approximately 15-25% when taking fish oil omega-3 fatty acid supplementation, irrespective of the degree of initial triglyceride elevation. This trial would thus represent a proof-of-concept study in children with mild to moderate hypertriglyceridemia.
The results of this study would contribute to the pool of knowledge regarding the efficacy and safety of this nutriceutical in the treatment of HAART-associated hypertriglyceridemia in children. Compared with other interventions (such as dietary changes and drug therapies), nutritional supplementation with fish oil is an inexpensive, simple, and likely preferable treatment for a potentially significant medical condition. In addition, the results of this study could presumably be extrapolated to benefit children with hypertriglyceridemia secondary to other types of drugs or illnesses.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children Taking Highly Active Antiretroviral Therapy (HAART): a Randomized Cross-over Study|
|Study Start Date :||June 2008|
|Primary Completion Date :||October 2011|
|Study Completion Date :||December 2012|
Drug: Omega Pure followed by placebo
Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
Other Name: omega-3 fatty acid supplementation
Drug: Placebo followed by Omega Pure
Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Other Name: Omega-3 fatty acid supplementation
- Percentage change in triglyceride levels [ Time Frame: 4 and 12 weeks after beginning treatment ]
- Changes in cholesterol profiles (LDL, HDL, and total:HDL ratio), amylase, platelet function, AST, and ALT [ Time Frame: 4 and 12 weeks after beginning treatment ]
- Reporting of side effects, compliance, and discontinuation [ Time Frame: 4 and 12 weeks after beginning treatment ]
- Effect on control of HIV (vial load, CD4) [ Time Frame: 12 weeks after beginning treatment ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691288
|The Hospital for Sick Children|
|Toronto, Ontario, Canada|
|Principal Investigator:||Ari Bitnun, MD, MSc||The Hospital for Sick Children|
|Principal Investigator:||Jason Brophy, MD||The Hospital for Sick Children|
|Principal Investigator:||Stanley Read, MD, PhD||The Hospital for Sick Children|